Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment.
about
Impaired carbohydrate digestion and transport and mucosal dysbiosis in the intestines of children with autism and gastrointestinal disturbancesIntestinal epithelium in inflammatory bowel diseaseEGL-9 controls C. elegans host defense specificity through prolyl hydroxylation-dependent and -independent HIF-1 pathwaysMicrobial ecology of the murine gut associated with the development of dextran sodium sulfate-induced colitis.Microbiota regulate intestinal epithelial gene expression by suppressing the transcription factor Hepatocyte nuclear factor 4 alphaCaspase-8 regulates TNF-α-induced epithelial necroptosis and terminal ileitis.Quantification of biological network perturbations for mechanistic insight and diagnostics using two-layer causal models.Whole genome gene expression meta-analysis of inflammatory bowel disease colon mucosa demonstrates lack of major differences between Crohn's disease and ulcerative colitis.Integrated miRNA and mRNA expression profiling in inflamed colon of patients with ulcerative colitis.An inducible and secreted eukaryote-like serine/threonine kinase of Salmonella enterica serovar Typhi promotes intracellular survival and pathogenesisEpigenetic regulation of lncRNA connects ubiquitin-proteasome system with infection-inflammation in preterm births and preterm premature rupture of membranesTranscriptomic landscape of lncRNAs in inflammatory bowel disease.DEFB1 gene 5' untranslated region (UTR) polymorphisms in inflammatory bowel diseases.The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancerILC3 GM-CSF production and mobilisation orchestrate acute intestinal inflammation.Intestinal APCs of the endogenous nanomineral pathway fail to express PD-L1 in Crohn's disease.Molecular patterns in human ulcerative colitis and correlation with response to infliximabCharacterization of candidate genes in inflammatory bowel disease-associated risk loci.The Gdac1 locus modifies spontaneous and Salmonella-induced colitis in mice deficient in either Gpx2 or Gpx1 gene.Immune activation in HIV/HCV-infected patients is associated with low-level expression of liver expressed antimicrobial peptide-2 (LEAP-2).Intestinal epithelial cells and their role in innate mucosal immunityReview article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-α therapy.Results of the 2nd scientific workshop of the ECCO (III): basic mechanisms of intestinal healing.Bioinformatics analysis reveals transcriptome and microRNA signatures and drug repositioning targets for IBD and other autoimmune diseases.Apoptosis, necrosis and necroptosis: cell death regulation in the intestinal epithelium.Targeting TNF-α for the treatment of inflammatory bowel disease.Intestinal barrier homeostasis in inflammatory bowel disease.Therapeutic innovations in inflammatory bowel diseases.The molecular biology of matrix metalloproteinases and tissue inhibitors of metalloproteinases in inflammatory bowel diseases.High-resolution gene expression profiling using RNA sequencing in patients with inflammatory bowel disease and in mouse models of colitis.Maintenance of macrophage transcriptional programs and intestinal homeostasis by epigenetic reader SP140Antimicrobial peptides in gastrointestinal inflammationOncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.Quantifying the relative immune cell activation from whole tissue/organ-derived differentially expressed gene data.Transcriptomic Landscape of Treatment - Naïve Ulcerative Colitis.Transcriptomics-driven lipidomics (TDL) identifies the microbiome-regulated targets of ileal lipid metabolism.Neutrophil gelatinase B-associated lipocalin and matrix metalloproteinase-9 complex as a surrogate serum marker of mucosal healing in ulcerative colitis.Transcriptional analysis of the intestinal mucosa of patients with ulcerative colitis in remission reveals lasting epithelial cell alterations.Reduction of CD68+ macrophages and decreased IL-17 expression in intestinal mucosa of patients with inflammatory bowel disease strongly correlate with endoscopic response and mucosal healing following infliximab therapy.Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro.
P2860
Q21560928-2382EF0E-5C68-4AFE-8EF7-8D1E34742CB7Q27022092-4491800F-A496-4D90-AE1A-F763911E2550Q27343881-E75E33B5-65FE-4E4E-B8B3-1D28A1E177B0Q33842489-718E438F-26B9-4697-BBAB-713252A4E2D8Q33865173-A92CC399-20F8-44B8-8681-D49CB5880F05Q34216810-4445D1FF-97A6-47A2-9137-3B6E3EB2B8D2Q34486361-1CB81E70-3923-4EE4-9F90-0EA4C7D0F31EQ34611580-9F00414C-53AC-4C38-A0EA-C0BF400408EEQ34784772-CC2966E8-F913-40A3-8362-35D14125FC2BQ34955506-A15F7EF6-F2CC-4D42-99DA-2E0A6BDBB0DBQ35104397-EB80EBC1-3471-402B-A926-0E0F8376DFA2Q35623787-182BB9D5-91E2-4C8A-900A-A802C8D4F099Q35865021-DC362DEA-5828-4AAF-87F9-45F252CE8824Q35996059-867B5133-17A2-4F39-995C-D14B836137B7Q36520874-AFC54545-8651-469B-B01F-36DAC8735445Q36937347-2C87E96B-876B-4276-BEE9-7E4AC73A78EDQ37175815-EEAEDD68-F6C5-4F2D-B2CA-E0991B58C5DEQ37275773-CF093786-1AD8-468E-A0E7-1BAF51B1F8F2Q37419561-9DB4AC1F-CBA2-4C4C-9ACA-79BED1758C7FQ37704680-0C1F4986-3B45-4C1D-9304-830C4F18649AQ37811994-B0F22B27-36B3-4C58-A1CA-C70C6CA4360BQ37871625-33E91C16-63E0-4BB3-9F4A-4004F7F131D2Q37992246-40AC03AB-0AFD-48D8-B9A1-13E86FD734EDQ38001400-7401C878-A34A-4FCC-A204-7AB4BA53BC50Q38018004-7F3E1573-8C8F-48ED-8BE5-853E63BEB3FCQ38160905-A77B5915-1E48-4DD0-914E-C84815A0F178Q38293757-5DF954E8-5A00-4CCD-B3EA-C790A63E3075Q38618178-D10EB7AC-4BD0-4CE2-B0CE-1C3E6AFF4539Q38881849-8B6BE866-EF8E-4268-85CD-6C1277E6DAB8Q41185159-D1786872-8927-43F3-9EA4-AE5FF8995257Q41321344-F7673F8C-CE40-4987-B128-E343DC3BF46AQ41477282-A4221F4A-39BD-4F12-838A-2A0EC0E4EB03Q41846031-0944EF2F-BD17-4636-A0E1-482289C4FCE2Q41921233-3DCA5AAC-AF4E-4A2B-9154-D2698335C283Q42778188-09AB7DC2-5529-467B-BAAA-D896D93C1909Q43557367-9DA85F08-D7FF-405E-A140-D9B6946A3CF2Q44304473-EE4C0141-77CB-4E89-8107-9D69E5DB2F6BQ44863098-B92888D7-1D33-4A37-BC52-0703146BEA53Q45611689-F702927A-C400-406E-B9B9-626EC5B93464Q45987643-1D93C578-061D-446C-80FF-153AFF721105
P2860
Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Mucosal gene expression of ant ...... er first infliximab treatment.
@ast
Mucosal gene expression of ant ...... er first infliximab treatment.
@en
type
label
Mucosal gene expression of ant ...... er first infliximab treatment.
@ast
Mucosal gene expression of ant ...... er first infliximab treatment.
@en
prefLabel
Mucosal gene expression of ant ...... er first infliximab treatment.
@ast
Mucosal gene expression of ant ...... er first infliximab treatment.
@en
P2093
P2860
P50
P1433
P1476
Mucosal gene expression of ant ...... er first infliximab treatment.
@en
P2093
Isabelle Cleynen
Katleen Lemaire
Peter Leemans
Roel Quintens
P2860
P356
10.1371/JOURNAL.PONE.0007984
P407
P50
P577
2009-11-24T00:00:00Z